Get the Stockscreener App
30.78
0.06%
-0.02
After Hours:
30.78
Edgewise Therapeutics Inc stock is traded at $30.78, with a volume of 1.06M.
It is down -0.06% in the last 24 hours and down -3.66% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
See More
Previous Close:
$30.80
Open:
$30.54
24h Volume:
1.06M
Relative Volume:
0.96
Market Cap:
$2.91B
Revenue:
-
Net Income/Loss:
$-115.88M
P/E Ratio:
-22.97
EPS:
-1.34
Net Cash Flow:
$-104.72M
1W Performance:
+11.44%
1M Performance:
-3.66%
6M Performance:
+83.11%
1Y Performance:
+261.69%
1-Day Range:
$30.06
$32.61
1-Week Range:
$28.00
$35.50
52-Week Range:
$8.64
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
30.78 | 2.91B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by State Street Corp - MarketBeat
What is Leerink Partnrs’ Forecast for EWTX FY2026 Earnings? - Defense World
Leerink Partnrs Has Strong Estimate for EWTX FY2026 Earnings - MarketBeat
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study - MSN
Short Interest in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Decreases By 10.2% - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of “Buy” by Analysts - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Expected to Rise, Evercore ISI Analyst Says - MarketBeat
EWTX Stock Rises On Upbeat Data From Rare Muscular Disorder Study - Barchart
Wellington Management Group LLP Sells 288,526 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease - AOL
Edgewise Therapeutics' SWOT analysis: stock poised for growth amid clinical milestones - Investing.com
Edgewise Therapeutics (NASDAQ:EWTX) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Edgewise weighs fast approval path for muscular dystrophy drug - BioPharma Dive
Edgewise Therapeutics (EWTX) Stock Jumps After Positive Trial News - Stocks Telegraph
Edgewise Therapeutics Shares Higher on Positive Trial Results - MarketWatch
Edgewise rises on mid-stage trial results for muscular dystrophy candidate - Seeking Alpha
Edgewise Therapeutics Shares Surge 21% on Positive Phase 2 CANYON Trial Results for Becker Muscular Dystrophy Drug - mediahousepress
Edgewise Therapeutics shares surge on positive trial results By Investing.com - Investing.com Australia
Edgewise Therapeutics shares surge on positive trial results - Investing.com India
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket - Benzinga
Edgewise's Muscular Dystrophy Drug Shows Promising 28% Reduction in Muscle Damage in Phase 2 Trial - StockTitan
Trading (EWTX) With Integrated Risk Controls - Stock Traders Daily
Edgewise distances from researcher criticized by FDA - BizWest
28,303 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Bought by XTX Topco Ltd - MarketBeat
Hypertrophic Cardiomyopathy Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Edgewise Therapeutics, Novartis, Lexicon Pharma, Shandong Suncadia Medicine, Ji Xing Pharma - Barchart
Hypertrophic Cardiomyopathy Market Forecasted to Surge - openPR
Fmr LLC Sells 4,127,355 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Sold by Frazier Life Sciences Management L.P. - MarketBeat
Charles Schwab Investment Management Inc. Sells 49,111 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Data-Based Insights About Edgewise Therapeutics Inc (EWTX) - Stocks Register
Edgewise confirms FDA compliance amid warning to researcher By Investing.com - Investing.com Canada
Truist maintains Buy on Edgewise Therapeutics, holds $50 target By Investing.com - Investing.com Canada
Edgewise confirms FDA compliance amid warning to researcher - Investing.com
Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research - Business Wire
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Sold by Polar Asset Management Partners Inc. - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stock Holdings Lifted by Janus Henderson Group PLC - MarketBeat
Glenmede Trust Co. NA Makes New Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics' SWOT analysis: biotech stock poised for growth amid clinical milestones - Investing.com Australia
Parkman Healthcare Partners LLC Has $17.54 Million Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
How the (EWTX) price action is used to our Advantage - Stock Traders Daily
HighVista Strategies LLC Makes New $2.37 Million Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
21,128 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Bought by Fred Alger Management LLC - MarketBeat
19,900 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Acquired by Intech Investment Management LLC - MarketBeat
Walleye Capital LLC Purchases New Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Braidwell LP Purchases Shares of 1,958,310 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Expected to Rise, Truist Financial Analyst Says - Defense World
Ally Bridge Group NY LLC Buys Shares of 187,695 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Acuta Capital Partners LLC Buys Shares of 63,000 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics shares target lifted, buy rating on positive outlook By Investing.com - Investing.com UK
Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 - BioSpace
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Edgewise Therapeutics Inc Stock (EWTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Russell Alan J | Chief Scientific Officer |
Sep 20 '24 |
Option Exercise |
0.18 |
75,000 |
13,500 |
87,719 |
| Russell Alan J | Chief Scientific Officer |
Sep 20 '24 |
Sale |
28.27 |
75,000 |
2,120,101 |
12,719 |
| MOORE JOHN R | General Counsel |
Sep 20 '24 |
Option Exercise |
0.71 |
50,000 |
35,500 |
53,252 |
| MOORE JOHN R | General Counsel |
Sep 23 '24 |
Option Exercise |
0.71 |
20,922 |
14,855 |
24,174 |
| MOORE JOHN R | General Counsel |
Sep 20 '24 |
Sale |
28.37 |
50,000 |
1,418,510 |
3,252 |
| MOORE JOHN R | General Counsel |
Sep 23 '24 |
Sale |
27.63 |
20,922 |
578,064 |
3,252 |
| Donovan Joanne M. | CMO |
Sep 20 '24 |
Sale |
28.29 |
7,162 |
202,603 |
14,538 |
| Derakhshan Behrad | Chief Business Officer |
Sep 20 '24 |
Option Exercise |
1.93 |
42,068 |
81,191 |
57,189 |
| Derakhshan Behrad | Chief Business Officer |
Sep 20 '24 |
Sale |
29.03 |
42,068 |
1,221,133 |
15,121 |
| Carruthers R Michael | Chief Financial Officer |
Sep 20 '24 |
Option Exercise |
1.93 |
96,068 |
185,411 |
81,996 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):